# LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

> **NCT05677308** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 61 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05677308
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-07
- **Primary completion:** 2026-02-18
- **Final completion:** 2026-02-18
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677308, "LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05677308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*